Recurrence of @entity149 ( @entity149 ) after initial diagnosis and treatment occurs within 2 years in most @entity1 , and relapse after 5 years is rare. We evaluated late relapse in our @entity149 population. We identified 10 @entity1 from our database of 378 @entity1 (268 achieved a complete response and 230 had relapse) with @entity149 who had relapse >= 5 years after initial diagnosis. At initial diagnosis, their median age was 47 years; all @entity1 had brain involvement and achieved a complete response to initial therapy (9 received high-dose @entity1499 ). Median time to first relapse was 7.4 years (range, 5.2-14.6 y). Eight @entity1 had relapse in the brain, 1 had ocular relapse, and 1 had a systemic relapse. The histologic specimens at initial diagnosis and relapse were examined for clonal rearrangement in 3 @entity1 ; 1 had the identical clone at initial diagnosis and relapse 13.8 years later, and the other 2 were uninformative. All @entity1 received salvage therapy (9 received systemic therapy and 1 received intraocular chemotherapy. Nine @entity1 achieved a complete response to salvage therapy and 1 achieved a partial response. Four @entity1 had relapse a second time. The median progression-free survival after first relapse was 31 months (range, 7.9-82.4). Late relapses accounted for 4% of all recurrences (10 of 230 @entity1 ) in our @entity149 population. Long-term persistence of the @entity149 clone was observed in one @entity1 . @entity1 with late relapses have a good response to salvage therapy and prolonged survival.

Late relapse in XXXX : clonal persistence.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity149 :: ('MESH:D002493', 'Disease') :: ['PCNSL', 'primary central nervous system lymphoma']
@entity149 :: (MESH:D002493,Disease) :: ['primary central nervous system lymphoma']
